Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study (Q33706623)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Identification of chronic kidney disease patient characteristics influencing the renoprotective effects of febuxostat therapy: a retrospective follow-up study (English)

1 reference

Europe PubMed Central

28 July 2017

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

author name string

Akinori Yamaguchi

1

1 reference

Europe PubMed Central

28 July 2017

Makoto Harada

2

1 reference

Europe PubMed Central

28 July 2017

Yosuke Yamada

3

1 reference

Europe PubMed Central

28 July 2017

Koji Hashimoto

4

1 reference

Europe PubMed Central

28 July 2017

Yuji Kamijo

5

1 reference

Europe PubMed Central

28 July 2017

publication date

18 May 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

18

1 reference

Europe PubMed Central

28 July 2017

162

1 reference

Europe PubMed Central

28 July 2017

1

1 reference

Europe PubMed Central

28 July 2017

https://scigraph.springernature.com/pub.10.1186/s12882-017-0572-z

0 references

Autophagy sequesters damaged lysosomes to control lysosomal biogenesis and kidney injury

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

Clinical outcome of hyperuricemia in IgA nephropathy: a retrospective cohort study and randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

The inflammasomes in kidney disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

Uric acid and long-term outcomes in CKD

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

Febuxostat compared with allopurinol in patients with hyperuricemia and gout

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

21 June 2018

Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats

1 reference

https://api.crossref.org/works/10.1186%2FS12882-017-0572-Z

21 January 2018

Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment

1 reference

https://api.crossref.org/works/10.1186%2FS12882-017-0572-Z

21 January 2018

Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia

1 reference

https://api.crossref.org/works/10.1186%2FS12882-017-0572-Z

21 January 2018

Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects.

1 reference

https://api.crossref.org/works/10.1186%2FS12882-017-0572-Z

21 January 2018

Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial

1 reference

https://api.crossref.org/works/10.1186%2FS12882-017-0572-Z

21 January 2018

Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial

1 reference

https://api.crossref.org/works/10.1186%2FS12882-017-0572-Z

21 January 2018

Oxidative stress with an activation of the renin-angiotensin system in human vascular endothelial cells as a novel mechanism of uric acid-induced endothelial dysfunction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

30 October 2018

Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5437587

30 October 2018

Serum Uric Acid Exhibits Inverse Relationship with Estimated Glomerular Filtration Rate

1 reference

https://api.crossref.org/works/10.1186%2FS12882-017-0572-Z

21 January 2018

An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan

1 reference

https://pubmed.ncbi.nlm.nih.gov/28521802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality

1 reference

https://pubmed.ncbi.nlm.nih.gov/28521802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum uric acid and renal prognosis in patients with IgA nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28521802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study

1 reference

https://pubmed.ncbi.nlm.nih.gov/28521802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/28521802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout

1 reference

https://pubmed.ncbi.nlm.nih.gov/28521802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Ja

1 reference

https://pubmed.ncbi.nlm.nih.gov/28521802

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12882-017-0572-Z

1 reference

Europe PubMed Central

28 July 2017

Dimensions Publication ID

1 reference

https://scigraph.springernature.com/pub.10.1186/s12882-017-0572-z

9 September 2019

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33706623&oldid=1601017066"